Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.

@article{Fontaine2014MajorBW,
  title={Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.},
  author={Gabriel V Fontaine and Katy D Mathews and Scott C. Woller and Scott M. Stevens and James F. Lloyd and R. Scott Evans},
  journal={Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis},
  year={2014},
  volume={20 7},
  pages={665-72}
}
BACKGROUND Although the rate of bleeding among patients with atrial fibrillation (AF) taking novel oral anticoagulants in randomized controlled trials is described, the rate of bleeding with "real-world" use is uncertain. METHODS We conducted a retrospective electronic medical record interrogation and subsequent chart review among patients within Intermountain Healthcare between October 2010 and November 2012. Patients were included if they had a diagnosis of AF and were receiving either… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS